We predict whether a given compound is capable of passing the blood brain barrier (> 93% accuracy). Additionally we can work with chemists to uncover structural features or changes that could improve blood-brain permeability.

Prediction of new indications for optimal disease subtypes (such as specific cancer types) for a given small molecule. Additionally by clustering new compounds in a network containing all approved drugs we can identify new mechanistic insights that could inform therapeutic positioning.

For a given genotype we predict gene essentiality, or the genes which, if lost or targetted, are likely to cause a severe loss of fitness (83% sccuracy to date). Additionally we can identify which genes are more likely to picked up as essential by an shRNA vs CRISPR screening protocol. Finally, using known drug targets and predicted gene essentiality we can estimate drug efficacy for a given genotype.

We predict whether a given compound is capable of passing the blood brain barrier (93% accuracy to date). Additionally we can work with chemists to uncover structural features or changes that could improve blood-brain permeability.

Integrating multiple different of pieces of information on a given compound (such as it's structure, screening data, transcriptional responses, etc.) we can predict its most likely binding targets and potential mechanism of action (91% accuracy to date).